SCHEDULE 13G: Prosight Entities Disclose 5.8% Stake in OnKure Therapeutics
Beneficial Ownership Disclosure (Schedule 13G)
Prosight Management, along with affiliated funds and its sole manager, W. Lawrence Hawkins, has disclosed a collective 5.8% beneficial ownership in OnKure Therapeutics, Inc.
Summary
- Prosight Management, LP, Prosight Partners, LLC, and W. Lawrence Hawkins each reported beneficial ownership of 745,649 shares of OnKure Therapeutics, Inc. Class A Common Stock.
- This aggregate ownership represents 5.8% of the outstanding Class A Common Stock of OnKure Therapeutics, Inc.
- The beneficial ownership is based on 12,861,672 shares of Class A Common Stock outstanding as of September 30, 2025.
- Prosight Fund, LP directly owns 35,514 shares (0.3%), and Prosight Plus Fund, LP directly owns 163,487 shares (1.3%).
- Prosight Management, LP serves as the general partner and investment manager for Prosight Fund, LP and Prosight Plus Fund, LP, and also sub-advises certain separate managed accounts.
- Prosight Partners, LLC is the general partner of Prosight Management, LP, and W. Lawrence Hawkins is the sole manager of Prosight Partners, LLC.
- The reporting persons certified that the securities were not acquired or held for the purpose of changing or influencing control of OnKure Therapeutics, Inc.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the issuer's performance or prospects. It simply reports a significant stake.
Positives
- A significant institutional investor group has taken a notable stake in OnKure Therapeutics, potentially signaling confidence in the company's future.
Negatives
- The filing itself does not contain negative information, as it is a disclosure of ownership.
Risks
- The filing explicitly states that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer, mitigating immediate concerns about activist investor intervention.
Future Outlook
NA
Industry Context
This filing indicates a significant passive investment by a group of related investment entities in OnKure Therapeutics, a company in the biotechnology or pharmaceutical sector, given its name. Such disclosures are common and reflect portfolio positioning by institutional investors.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake may be viewed positively, indicating investor interest and potentially providing a level of stability to the stock. The explicit disclaimer of intent to influence control suggests a passive investment approach.
Key Dates
| Date | Description |
|---|---|
| 2025-09-30 | Date as of which 12,861,672 shares of Class A Common Stock were outstanding, used for percentage calculation. |
| 2025-11-21 | Date OnKure Therapeutics, Inc.'s prospectus was filed with the SEC, disclosing outstanding share count. |
| 2025-11-24 | Date of event which required the filing of this Schedule 13G statement. |
| 2025-11-28 | Date the Schedule 13G statement and Joint Filing Agreement were executed and filed. |
Keywords
OnKure Therapeutics, Prosight Management, Schedule 13G, Beneficial Ownership, Class A Common Stock, Institutional Investor, SEC Filing, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.